Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2012, Article ID 637316, 7 pages
http://dx.doi.org/10.1155/2012/637316
Review Article

New Approach of Anti-VEGF Agents for Age-Related Macular Degeneration

Department of Ophthalmology, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, No. 62 Yeouido-dong, Yeongdeungpo-gu, Seoul 150-713, Republic of Korea

Received 30 July 2011; Accepted 3 November 2011

Academic Editor: Yoshiaki Kiuchi

Copyright © 2012 Young Gun Park et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. M. Bressler, “Age-related macular degeneration is the leading cause of blindness,” Journal of the American Medical Association, vol. 291, no. 15, pp. 1900–1901, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. M. V. Emerson and A. K. Lauer, “Current and emerging therapies for the treatment of age-related macular degeneration,” Clinical Ophthalmology, vol. 2, no. 2, pp. 377–388, 2008. View at Google Scholar
  3. D. T. Shima, A. P. Adamis, N. Ferrara et al., “Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen,” Molecular Medicine, vol. 1, no. 2, pp. 182–193, 1995. View at Google Scholar · View at Scopus
  4. N. Ferrara, H. P. Gerber, and J. LeCouter, “The biology of VEGF and its receptors,” Nature Medicine, vol. 9, no. 6, pp. 669–676, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Kliffen, H. S. Sharma, C. M. Mooy, S. Kerkvliet, and P. T. V. M. De Jong, “Increased expression of angiogenic growth factors in age-related maculopathy,” British Journal of Ophthalmology, vol. 81, no. 2, pp. 154–162, 1997. View at Google Scholar · View at Scopus
  6. E. S. Gragoudas, A. P. Adamis, E. T. Cunningham, M. Feinsod, and D. R. Guyer, “Pegaptanib for neovascular age-related macular degeneration,” New England Journal of Medicine, vol. 351, no. 27, pp. 2805–2816, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. D. M. Brown, P. K. Kaiser, M. Michels et al., “Ranibizumab versus verteporfin for neovascular age-related macular degeneration,” New England Journal of Medicine, vol. 355, no. 14, pp. 1432–1444, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. D. M. Brown, M. Michels, P. K. Kaiser, J. S. Heier, J. P. Sy, and T. Ianchulev, “Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study,” Ophthalmology, vol. 116, no. 1, pp. 57–65.e5, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. P. J. Rosenfeld, D. M. Brown, J. S. Heier et al., “Ranibizumab for neovascular age-related macular degeneration,” New England Journal of Medicine, vol. 355, no. 14, pp. 1419–1431, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. P. K. Kaiser, B. A. Blodi, H. Shapiro, and N. R. Acharya, “Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration,” Ophthalmology, vol. 114, no. 10, pp. 1868–1875, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. S. R. Sadda, G. Stoller, D. S. Boyer, B. A. Blodi, H. Shapiro, and T. Ianchulev, “Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age-related macular degeneration in the 2-year ANCHOR study,” Retina, vol. 30, no. 9, pp. 1390–1399, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. R. F. Spaide, K. Laud, H. F. Fine et al., “Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration,” Retina, vol. 26, no. 4, pp. 383–390, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. M. V. Emerson, A. K. Lauer, C. J. Flaxel et al., “Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration,” Retina, vol. 27, no. 4, pp. 439–444, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. C. A. Cleary, S. Jungkim, K. Ravikumar, C. Kelliher, R. W. Acheson, and M. Hickey-Dwyer, “Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results,” Eye, vol. 22, no. 1, pp. 82–86, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. P. Yoganathan, V. A. Deramo, J. C. Lai, R. K. Tibrewala, and D. M. Fastenberg, “Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration,” Retina, vol. 26, no. 9, pp. 994–998, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. R. L. Avery, D. J. Pieramici, M. D. Rabena, A. A. Castellarin, M. A. Nasir, and M. J. Giust, “Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration,” Ophthalmology, vol. 113, no. 3, pp. 363–372, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. Z. F. Bashshur, Z. A. Haddad, A. Schakal, R. F. Jaafar, M. Saab, and B. N. Noureddin, “Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study,” American Journal of Ophthalmology, vol. 145, no. 2, pp. 249–256, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. P. V. Algvere, B. Steén, S. Seregard, and A. Kvanta, “A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations,” Acta Ophthalmologica, vol. 86, no. 5, pp. 482–489, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. L. Wu, M. A. Martínez-Castellanos, H. Quiroz-Mercado et al., “Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the pan-american collaborative retina study group (PACORES),” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 246, no. 1, pp. 81–87, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. D. F. Martin, M. G. Maguire, G.-S. Ying, J. E. Grunwald, S. L. Fine, and G. J. Jaffe, “Ranibizumab and bevacizumab for neovascular age-related macular degeneration,” New England Journal of Medicine, vol. 364, no. 20, pp. 1897–1908, 2011. View at Publisher · View at Google Scholar
  21. P. J. Rosenfeld, “Bevacizumab versus ranibizumab for AMD,” New England Journal of Medicine, vol. 364, no. 20, pp. 1966–1967, 2011. View at Publisher · View at Google Scholar
  22. C. D. Regillo, D. M. Brown, P. Abraham et al., “Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1,” American Journal of Ophthalmology, vol. 145, no. 2, pp. 239–248, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. P. Abraham, H. Yue, and L. Wilson, “Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2,” American Journal of Ophthalmology, vol. 150, no. 3, pp. 315–324, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. U. Schmidt-Erfurth, B. Eldem, R. Guymer et al., “Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration. The EXCITE study,” Ophthalmology, vol. 118, no. 5, pp. 831–839, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Spaide, “Ranibizumab according to need: a treatment for age-related macular degeneration,” American Journal of Ophthalmology, vol. 143, no. 4, pp. 679–680, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. D. M. Brown and C. D. Regillo, “Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients,” American Journal of Ophthalmology, vol. 144, no. 4, pp. 627–637, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Chiang and C. D. Regillo, “Preferred therapies for neovascular age-related macular degeneration,” Current Opinion in Ophthalmology, vol. 22, no. 3, pp. 199–204, 2011. View at Publisher · View at Google Scholar
  28. G. A. Lalwani, P. J. Rosenfeld, A. E. Fung et al., “A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study,” American Journal of Ophthalmology, vol. 148, no. 1, pp. 43–58, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. D. S. Boyer, J. S. Heier, D. M. Brown, S. F. Francom, T. Ianchulev, and R. G. Rubio, “A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration,” Ophthalmology, vol. 116, no. 9, pp. 1731–1739, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. Y. Tano and M. Ohji, “EXTEND-I: safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration,” Acta Ophthalmologica, vol. 88, no. 3, pp. 309–316, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. H. Dadgostar, A. A. C. M. Ventura, J. Y. Chung, S. Sharma, and P. K. Kaiser, “Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration,” Ophthalmology, vol. 116, no. 9, pp. 1740–1747, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. S. P. Rothenbuehler, D. Waeber, C. K. Brinkmann, S. Wolf, and U. E. K. Wolf-Schnurrbusch, “Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration,” American Journal of Ophthalmology, vol. 147, no. 5, pp. 831–837, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. O. P. Gupta, G. Shienbaum, A. H. Patel, C. Fecarotta, R. S. Kaiser, and C. D. Regillo, “A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration: clinical and economic impact,” Ophthalmology, vol. 117, no. 11, pp. 2134–2140, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Kang and Y. J. Roh, “Ranibizumab treatment administered as needed for occult and minimally classic neovascular membranes in age-related macular degeneration,” Japanese Journal of Ophthalmology, vol. 55, no. 2, pp. 123–127, 2011. View at Publisher · View at Google Scholar
  35. S. Kang and Y. J. Roh, “One-year results of intravitreal ranibizumab for neovascular age-related macular degeneration and clinical responses of various subgroups,” Japanese Journal of Ophthalmology, vol. 53, no. 4, pp. 389–395, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. P. M. Beer, S. J. Bakri, R. J. Singh, W. Liu, G. B. Peters, and M. Miller, “Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection,” Ophthalmology, vol. 110, no. 4, pp. 681–686, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. A. F. Cruess, G. Zlateva, A. M. Pleil, and B. Wirostko, “Photodynamic therapy with verteporfin in age-related macular degeneration: a systematic review of efficacy, safety, treatment modifications and pharmacoeconomic properties,” Acta Ophthalmologica, vol. 87, no. 2, pp. 118–132, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Arnold, I. Barbezetto, R. Birngruber et al., “Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—verteporfin in photodynamic therapy report 2,” American Journal of Ophthalmology, vol. 131, no. 5, pp. 541–560, 2001. View at Publisher · View at Google Scholar · View at Scopus
  39. A. N. Antoszyk, L. Tuomi, C. Y. Chung, and A. Singh, “Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results,” American Journal of Ophthalmology, vol. 145, no. 5, pp. 862–874, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. J. S. Heier, D. S. Boyer, T. A. Ciulla et al., “Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS study,” Archives of Ophthalmology, vol. 124, no. 11, pp. 1532–1542, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. “Aflibercept: AVE 0005, AVE 005, AVE0005, VEGF trap—regeneron, VEGF trap (R1R2), VEGF trap-eye,” Drugs in R and D, vol. 9, no. 4, pp. 261–269, 2008.
  42. J. A. Dixon, S. C. N. Oliver, J. L. Olson, and N. Mandava, “VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration,” Expert Opinion on Investigational Drugs, vol. 18, no. 10, pp. 1573–1580, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. J. Beutel, M. Rudolf, and S. Grisanti, “Current and future therapies for age-related macular degeneration,” Expert Opinion on Emerging Drugs, vol. 14, no. 2, pp. 341–362, 2009. View at Publisher · View at Google Scholar · View at Scopus